OBJECTIVE: To determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma. METHODS: Patients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified. Clinical and pathologic data were retrospectively collected. HER-2/neu, estrogen and progesterone receptor expression were determined by immunohistochemistry. Differences in these variables and other prognostic factors were analyzed and correlated with effect on survival. RESULTS: One-hundred-sixty-five patients were included in this analysis. Lower BMI was associated with high stage (p=0.04) and HER-2/neu expression (p=0.04). Black race, high grade, high stage and lack of ER/PR expression were all associated with decreased survival. Despite having better prognostic factors, women with a BMI >25 had a lower survival than women with a BMI <25 (p=0.36). When five-year survival rates were calculated for BMI category and stratified by prognostic factors, for almost every high risk factor, survival was lower in overweight patients. CONCLUSION: In patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu. Despite better prognostic factors, overweight women experience poorer survival.
OBJECTIVE: To determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma. METHODS:Patients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified. Clinical and pathologic data were retrospectively collected. HER-2/neu, estrogen and progesterone receptor expression were determined by immunohistochemistry. Differences in these variables and other prognostic factors were analyzed and correlated with effect on survival. RESULTS: One-hundred-sixty-five patients were included in this analysis. Lower BMI was associated with high stage (p=0.04) and HER-2/neu expression (p=0.04). Black race, high grade, high stage and lack of ER/PR expression were all associated with decreased survival. Despite having better prognostic factors, women with a BMI >25 had a lower survival than women with a BMI <25 (p=0.36). When five-year survival rates were calculated for BMI category and stratified by prognostic factors, for almost every high risk factor, survival was lower in overweight patients. CONCLUSION: In patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu. Despite better prognostic factors, overweight women experience poorer survival.
Authors: Wang Hong Xu; Charles E Matthews; Yong Bing Xiang; Wei Zheng; Zhi Xian Ruan; Jia Rong Cheng; Yu Tang Gao; Xiao Ou Shu Journal: Am J Epidemiol Date: 2005-05-15 Impact factor: 4.897
Authors: Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle Journal: Gynecol Oncol Date: 2013-02-21 Impact factor: 5.482
Authors: Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg Journal: Oncologist Date: 2019-06-11
Authors: Hannah Arem; Yikyung Park; Colleen Pelser; Rachel Ballard-Barbash; Melinda L Irwin; Albert Hollenbeck; Gretchen L Gierach; Louise A Brinton; Ruth M Pfeiffer; Charles E Matthews Journal: J Natl Cancer Inst Date: 2013-01-07 Impact factor: 13.506
Authors: Angeles Alvarez Secord; Vic Hasselblad; Vivian E Von Gruenigen; Paola A Gehrig; Susan C Modesitt; Victoria Bae-Jump; Laura J Havrilesky Journal: Gynecol Oncol Date: 2015-10-31 Impact factor: 5.482
Authors: Ashley S Felix; D Scott McMeekin; David Mutch; Joan L Walker; William T Creasman; David E Cohn; Shamshad Ali; Richard G Moore; Levi S Downs; Olga B Ioffe; Kay J Park; Mark E Sherman; Louise A Brinton Journal: Gynecol Oncol Date: 2015-09-01 Impact factor: 5.482
Authors: K K Mauland; J Trovik; E Wik; M B Raeder; T S Njølstad; I M Stefansson; A M Oyan; K H Kalland; T Bjørge; L A Akslen; H B Salvesen Journal: Br J Cancer Date: 2011-02-22 Impact factor: 7.640
Authors: Frances Collins; Sheila MacPherson; Pamela Brown; Vincent Bombail; Alistair R W Williams; Richard A Anderson; Henry N Jabbour; Philippa T K Saunders Journal: BMC Cancer Date: 2009-09-16 Impact factor: 4.430